{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:50:23Z","timestamp":1787629823178,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03199-3","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:24:40Z","timestamp":1745562280000},"page":"2874-2887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["LDL-C Reduction with Evolocumab Among Patients with ASCVD in China: Real-World Evidence from Tianjin Metropolitan Area"],"prefix":"10.1007","volume":"42","author":[{"given":"Liming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenna","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff L.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafeesa","family":"Dhalwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2590-8667","authenticated-orcid":false,"given":"Jifang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"3199_CR1","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020\/10\/19 ed2020. p. 1204\u201322."},{"key":"3199_CR2","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934.","journal-title":"Front Pharmacol"},{"issue":"10204","key":"3199_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145\u201358.","journal-title":"Lancet"},{"key":"3199_CR4","doi-asserted-by":"crossref","unstructured":"Wang Z, Ma L, Liu M, Fan J, Hu S, Writing Committee of the Report on Cardiovascular Health and Diseases in China. Summary of the 2022 Report on Cardiovascular Health and Diseases in China. Chin Med J (Engl). 2023;136(24):2899\u2013908.","DOI":"10.1097\/CM9.0000000000002927"},{"key":"3199_CR5","doi-asserted-by":"crossref","unstructured":"Sun P, Zhao L, Zhang N, et al. Bioactivity of dietary polyphenols: the role in LDL-C lowering. Foods. 2021;10(11):2666.","DOI":"10.3390\/foods10112666"},{"issue":"11","key":"3199_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028892","volume":"12","author":"MJ Wilkinson","year":"2023","unstructured":"Wilkinson MJ, Lepor NE, Michos ED. Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum. J Am Heart Assoc. 2023;12(11):e028892.","journal-title":"J Am Heart Assoc"},{"issue":"34","key":"3199_CR7","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","volume":"43","author":"L Tokgozoglu","year":"2022","unstructured":"Tokgozoglu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022;43(34):3198\u2013208.","journal-title":"Eur Heart J"},{"issue":"3","key":"3199_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389\u201395.","journal-title":"Drugs"},{"issue":"25","key":"3199_CR9","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"8","key":"3199_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11886-020-01326-w","volume":"22","author":"L Masana","year":"2020","unstructured":"Masana L, Ibarretxe D, Plana N. Reasons why combination therapy should be the new standard of care to achieve the LDL-cholesterol targets: lipid-lowering combination therapy. Curr Cardiol Rep. 2020;22(8):66.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"3199_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/ehjcvp\/pvv045","volume":"2","author":"EP Navarese","year":"2016","unstructured":"Navarese EP, Kolodziejczak M, Dimitroulis D, et al. From proprotein convertase subtilisin\/kexin type\u00a09 to its inhibition: state-of-the-art and clinical implications. Eur Heart J Cardiovasc Pharmacother. 2016;2(1):44\u201353.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3199_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ahj.2016.06.005","volume":"179","author":"Y Hao","year":"2016","unstructured":"Hao Y, Liu J, Liu J, et al. Rationale and design of the improving care for cardiovascular disease in China (CCC) project: a national effort to prompt quality enhancement for acute coronary syndrome. Am Heart J. 2016;179:107\u201315.","journal-title":"Am Heart J"},{"issue":"1142","key":"3199_CR13","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/postgradmedj-2019-137008","volume":"96","author":"J Li","year":"2020","unstructured":"Li J, Peng H, Zhao X, et al. Analysis of situation of acute coronary syndrome based on the date of the improving care for cardiovascular disease in China-acute coronary syndrome (CCC-ACS) project: single-centre observational study. Postgrad Med J. 2020;96(1142):742\u20136.","journal-title":"Postgrad Med J"},{"issue":"1","key":"3199_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12933-018-0793-x","volume":"17","author":"M Zhou","year":"2018","unstructured":"Zhou M, Liu J, Hao Y, et al. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Cardiovasc Diabetol. 2018;17(1):147.","journal-title":"Cardiovasc Diabetol"},{"key":"3199_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.839571","volume":"9","author":"L Bi","year":"2022","unstructured":"Bi L, Yi J, Wu C, et al. Atherosclerotic cardiovascular disease risk and lipid-lowering therapy requirement in China. Front Cardiovasc Med. 2022;9:839571.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"3199_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016195","volume":"7","author":"M Su","year":"2017","unstructured":"Su M, Zhang Q, Lu J, et al. Protocol for a nationwide survey of primary health care in China: the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) MPP (Million Persons Project) Primary Health Care Survey. BMJ Open. 2017;7(8):e016195.","journal-title":"BMJ Open"},{"key":"3199_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2022.03.027","volume":"350","author":"H Teng","year":"2022","unstructured":"Teng H, Gao Y, Wu C, et al. Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35\u201375\u00a0years: results from China PEACE million persons project. Atherosclerosis. 2022;350:58\u201364.","journal-title":"Atherosclerosis"},{"issue":"2","key":"3199_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.33963\/KP.a2023.0030","volume":"81","author":"SJ Nicholls","year":"2023","unstructured":"Nicholls SJ. PCSK9 inhibitors and reduction in cardiovascular events: current evidence and future perspectives. Kardiol Pol. 2023;81(2):115\u201322.","journal-title":"Kardiol Pol"},{"key":"3199_CR19","doi-asserted-by":"crossref","unstructured":"Blom DJ, Dent R, Castro RC, Toth PP. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vasc Health Risk Manag. 2016;12:185\u201397.","DOI":"10.2147\/VHRM.S102564"},{"issue":"18","key":"3199_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"3199_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083683","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Guo Y, Zhang K, et al. Comorbidities among adult patients with psoriasis in Tianjin: a cross-sectional analysis of the Health Database study. BMJ Open. 2024;14(5):e083683.","journal-title":"BMJ Open"},{"issue":"1","key":"3199_CR22","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1186\/s12889-023-17280-5","volume":"23","author":"M Wang","year":"2023","unstructured":"Wang M, He Y, He Q, et al. Comparison of clinical characteristics and disease burden between early- and late-onset type\u00a02 diabetes patients: a population-based cohort study. BMC Public Health. 2023;23(1):2411.","journal-title":"BMC Public Health"},{"key":"3199_CR23","doi-asserted-by":"publisher","first-page":"1037564","DOI":"10.3389\/fendo.2022.1037564","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang Y, Yang C, et al. Naoxintong capsule delay the progression of diabetic kidney disease: a real-world cohort study. Front Endocrinol (Lausanne). 2022;13:1037564.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3199_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8\u201335.","journal-title":"Psychother Psychosom"},{"issue":"5","key":"3199_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"5","key":"3199_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/clc.23600","volume":"44","author":"NR Desai","year":"2021","unstructured":"Desai NR, Wade RL, Xiang P, et al. Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab. Clin Cardiol. 2021;44(5):715\u201322.","journal-title":"Clin Cardiol"},{"issue":"1","key":"3199_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12325-021-01962-w","volume":"39","author":"D Nanchen","year":"2022","unstructured":"Nanchen D, Carballo D, Bilz S, et al. Effectiveness, adherence, and safety of evolocumab in a swiss multicenter prospective observational study. Adv Ther. 2022;39(1):504\u201317.","journal-title":"Adv Ther"},{"issue":"3\u20134","key":"3199_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00508-023-02245-w","volume":"136","author":"C Ebenbichler","year":"2024","unstructured":"Ebenbichler C, Drexel H, Hanusch U, et al. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study. Wien Klin Wochenschr. 2024;136(3\u20134):77\u201386.","journal-title":"Wien Klin Wochenschr"},{"key":"3199_CR29","doi-asserted-by":"crossref","unstructured":"Kim MC, Lee SH, Ahn JH, et al. Real-world application of evolocumab among patients with hyperlipidemia in Korea: a multicenter prospective study. Cardiol Ther. 2024;13(4):695\u2013706.","DOI":"10.1007\/s40119-024-00389-y"},{"key":"3199_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.002","volume":"366","author":"KK Ray","year":"2023","unstructured":"Ray KK, Bruckert E, Peronne-Filardi P, et al. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30\u00a0months: final results from the European observational HEYMANS study. Atherosclerosis. 2023;366:14\u201321.","journal-title":"Atherosclerosis"},{"issue":"4","key":"3199_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40119-023-00334-5","volume":"12","author":"M Gupta","year":"2023","unstructured":"Gupta M, Wani RJ, Al Faraidy K, et al. Real-world insights into evolocumab use in patients with hyperlipidemia across five countries: analysis from the ZERBINI study. Cardiol Ther. 2023;12(4):703\u201322.","journal-title":"Cardiol Ther"},{"issue":"4","key":"3199_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40119-024-00384-3","volume":"13","author":"H-F Tse","year":"2024","unstructured":"Tse H-F, Chang H-Y, Colquhoun D, et al. Asia-Pacific real-world evolocumab use, LDL-C reduction, physician goals, and patient perceptions: HALES observational study. Cardiol Ther. 2024;13(4):737\u201360.","journal-title":"Cardiol Ther"},{"issue":"3","key":"3199_CR33","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/MJT.0000000000001373","volume":"30","author":"S Hui-Wei","year":"2023","unstructured":"Hui-Wei S, Wen-Jia Z, Yan Z, et al. Evolocumab application in real world from a single-center registry in China. Am J Ther. 2023;30(3):e293\u20136.","journal-title":"Am J Ther"},{"issue":"11","key":"3199_CR34","first-page":"1358","volume":"136","author":"M Chai","year":"2023","unstructured":"Chai M, Zhang H, Yang L, et al. Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study. Chin Med J (Engl). 2023;136(11):1358\u201360.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"3199_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2174\/1570161118666200616144141","volume":"19","author":"X Xu","year":"2021","unstructured":"Xu X, Chai M, Cheng Y, et al. Efficacy and safety of evolocumab in reducing low-density lipoprotein cholesterol levels in chinese patients with non-ST-segment elevation acute coronary syndrome. Curr Vasc Pharmacol. 2021;19(4):429\u201337.","journal-title":"Curr Vasc Pharmacol"},{"issue":"6","key":"3199_CR36","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.clinthera.2022.04.010","volume":"44","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhang Y, Zhang B, et al. Early initiation of evolocumab treatment in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clin Ther. 2022;44(6):901\u201312.","journal-title":"Clin Ther"},{"issue":"4","key":"3199_CR37","first-page":"261","volume":"18","author":"YQ Liu","year":"2021","unstructured":"Liu YQ, Li DD, Chai M, et al. Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study). J Geriatr Cardiol. 2021;18(4):261\u201370.","journal-title":"J Geriatr Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03199-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03199-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T07:59:53Z","timestamp":1747468793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03199-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3199"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03199-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zhenna Huang, Xuxiao Ye, Jeff L. Lange, Nafeesa Dhalwani are Amgen employees. Zhenna Huang, Jeff L. Lange, Nafeesa Dhalwani are Amgen stockholders. All other authors (Liming Zhao, Jiamei Liu, Yin Liu, Fan Yang, Zizhao Zhang, Kangyin Chen, Hao Zhang and Jifang Zhou) declare no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All listed authors meet the authorship requirements as detailed in the ICMJE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by the Institutional Review Board of The Second Hospital of Tianjin Medical University and China Pharmaceutical University (2024-09-137). This study was performed in accordance with the Helsinki Declaration of 1964. Patient informed consent was waived as the data source was anonymized. All authors have approved the publication of this study. Data from TRHD can only be analyzed on the secured site by qualified investigators and the principal investigator\u2019s team had permission to access the database from database owner.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}